Private equity firm GTCR has agreed to acquire Czech generic drugmaker Zentiva from Advent International in a transaction valued at €4.1 billion ($4.8 billion), according to reports in the Financial Times. The deal, which is expected to be formally announced in the coming days, marks one of the largest recent buyouts in the European generics market.
According to Reuters, Aurobindo Pharma was previously reported as a frontrunner to acquire Zentiva in a bid of up to $5.5 billion, underscoring Indian pharma’s interest in expanding its global generics footprint. Advent had originally purchased Zentiva from Sanofi in 2018 for €1.9 billion, and has since scaled its operations.
Zentiva, headquartered in Prague, manufactures a wide portfolio of generic and over-the-counter medicines and operates across more than 30 countries with a workforce of over 5,000. The acquisition reflects ongoing consolidation in the global generics sector, where private equity and strategic investors are targeting scalable platforms with strong geographic presence.
For Indian firms, the development highlights intensifying competition for European assets. While GTCR secures Zentiva, the appetite among Indian companies for overseas acquisitions suggests continued outbound interest in generics, biosimilars, and specialty pharma.
